On Jun. 2, 2020, the NIH reported that early results showed that remdesivir benefited hospitalized patients with severe COVID-19 who required supplemental oxygen. While the findings support remdesivir as a standard therapy for such patients, they suggest more research is needed to improve outcomes for people with COVID-19.